*Acadia finished down last night at $21.99 per share on volume about double the stated average volume. *ACADIA Pharmaceuticals (ACAD Financial) has received significant attention from RBC Capital as analyst Gregory Renza reiterates an "Outperform" rating on the stock. This action highlights the steady confidence that RBC Capital holds towards ACAD's market potential.The price target for ACAD remains unchanged at $26.00 USD consistent with prior evaluations. The stable price target indicates confidence in the company's current trajectory without any adjustment necessary at this time. *Gregory Renza of RBC Capital has been referred to in the past as the Acadia "house broker" with Acadia stock ratings often more favourable than many of his peers. Kens
NEU Price at posting:
$12.87 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)